Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 3693096, 10 pages
http://dx.doi.org/10.1155/2016/3693096
Research Article

Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer

1Department of Functional Genomics, Institute of Molecular Biology and Genetics of the National Academy of Science of Ukraine, Kyiv, Ukraine
2Department of Molecular Oncogenetics, Institute of Molecular Biology and Genetics of the National Academy of Science of Ukraine, Kyiv, Ukraine
3Institute of Urology, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine

Received 10 June 2016; Revised 19 August 2016; Accepted 22 August 2016

Academic Editor: Olav Lapaire

Copyright © 2016 Inessa Skrypkina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Banumathy and P. Cairns, “Signaling pathways in renal cell carcinoma,” Cancer Biology and Therapy, vol. 10, no. 7, pp. 658–664, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Gupta, J. D. Miller, J. Z. Li, M. W. Russell, and C. Charbonneau, “Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review,” Cancer Treatment Reviews, vol. 34, no. 3, pp. 193–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. Ministry of Healthcare of Ukraine, The Features Diagnosis and Prognosis Factors Renal Cell Carcinoma, Ministry of Healthcare of Ukraine, 2011, http://www.souu.org.ua.
  4. World Cancer Research Fund International/American Institute for Cancer Research, Continuous Update Project Report: Diet, Nutrition, Physical Activity and Kidney Cancer, 2015.
  5. A. Lopez-Beltran, M. Scarpelli, R. Montironi, and Z. Kirkali, “2004 WHO classification of the renal tumors of the adults,” European Urology, vol. 49, no. 5, pp. 798–805, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Hadaczek, Z. Siprashvili, M. Markiewski et al., “Absence or reduction of FHIT expression in most clear cell renal carcinomas,” Cancer Research, vol. 58, no. 14, pp. 2946–2951, 1998. View at Google Scholar · View at Scopus
  7. E. Arai and Y. Kanai, “Genetic and epigenetic alterations during renal carcinogenesis,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 1, pp. 58–73, 2011. View at Google Scholar · View at Scopus
  8. B. N. Lasseigne, T. C. Burwell, M. A. Patil, D. M. Absher, J. D. Brooks, and R. M. Myers, “DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma,” BMC Medicine, vol. 12, no. 1, article 235, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Shenoy, N. Vallumsetla, Y. Zou et al., “Role of DNA methylation in renal cell carcinoma,” Journal of Hematology and Oncology, vol. 8, no. 1, article 88, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. G. J. Fournié, J.-P. Courtin, F. Laval et al., “Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours,” Cancer Letters, vol. 91, no. 2, pp. 221–227, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Schwarzenbach, D. S. B. Hoon, and K. Pantel, “Cell-free nucleic acids as biomarkers in cancer patients,” Nature Reviews Cancer, vol. 11, no. 6, pp. 426–437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Taback and D. S. B. Hoon, “Circulating nucleic acids and proteomics of plasma/serum: clinical utility,” Annals of the New York Academy of Sciences, vol. 1022, pp. 1–8, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Wasserkort, A. Kalmar, G. Valcz et al., “Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island,” BMC Cancer, vol. 13, article 398, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Ya. Skrypkina, V. I. Kashuba, V. V. Gordiyuk et al., “Identification of changes in gene loci potentially associated with renal cancer by novel technique of NotI microarrays,” Reports of the National Academy of Sciences of Ukraine, vol. 11, pp. 188–192, 2006. View at Google Scholar
  15. V. I. Kashuba, I. Y. Skrypkina, D. V. Saraev et al., “Identification of changes in gene loci potentially associated with cervical cancer using NotI microarrays,” Ukrain'skyi Biokhimichnyi Zhurnal, vol. 78, no. 2, pp. 113–120, 2006. View at Google Scholar · View at Scopus
  16. V. I. Loginov, D. S. Khodyrev, I. V. Pronina et al., “Methylation of the RASSF1A promoter region and the allelic imbalance frequencies in chromosome 3 critical regions correlate with progression of clear cell renal carcinoma,” Molecular Biology, vol. 43, no. 3, pp. 394–402, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Peters, K. Rehmet, N. Wilke et al., “RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis,” Molecular Cancer, vol. 6, article 49, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Hauser, T. Zahalka, and G. Fechner, “Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study,” Anticancer Research, vol. 33, pp. 4651–4656, 2013. View at Google Scholar
  19. M. De Martino, T. Klatte, A. Haitel, and M. Marberger, “Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker,” Cancer, vol. 118, no. 1, pp. 82–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. O. Hoque, S. Begum, O. Topaloglu et al., “Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer,” Cancer Research, vol. 64, no. 15, pp. 5511–5517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Ramp, E. Caliskan, T. Ebert et al., “FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival,” The Journal of Pathology, vol. 196, no. 4, pp. 430–436, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Kvasha, V. Gordiyuk, A. Kondratov et al., “Hypermethylation of the 5′CpG island of the FHIT gene in clear cell renal carcinomas,” Cancer Letters, vol. 265, no. 2, pp. 250–257, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. L. J. Herrera, S. Raja, W. E. Gooding et al., “Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies,” Clinical Chemistry, vol. 51, no. 1, pp. 113–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Czeiger, G. Shaked, H. Eini et al., “Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer,” American Journal of Clinical Pathology, vol. 135, no. 2, pp. 264–270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. J. G. Herman, J. R. Graff, S. Myöhänen, B. D. Nelkin, and S. B. Baylin, “Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9821–9826, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Lo, J. Kwong, A. B. Hui et al., “Advances in brief high frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma,” Journal of Clinical Oncology, pp. 3877–3881, 2001. View at Google Scholar
  27. S. Zöchbauer-Müller, K. M. Fong, A. Maitra et al., “5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer,” Cancer Research, vol. 61, no. 9, pp. 3581–3585, 2001. View at Google Scholar · View at Scopus
  28. M. Shinozaki, D. S. B. Hoon, A. E. Giuliano et al., “Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis,” Clinical Cancer Research, vol. 11, no. 6, pp. 2156–2162, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. A. G. Kondratov, L. A. Stoliar, S. M. Kvasha et al., “Methylation pattern of the putative tumor-suppressor gene LRRC3B promoter in clear cell renal cell carcinomas,” Molecular Medicine Reports, vol. 5, no. 2, pp. 509–512, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Kuroki, F. Trapasso, S. Yendamuri et al., “Allele loss and promoter hypermethylation of VHL, RAR-β, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma,” Cancer Research, vol. 63, no. 13, pp. 3724–3728, 2003. View at Google Scholar · View at Scopus
  31. J.-L. Li, Q. Fei, J. Yu, H.-Y. Zhang, P. Wang, and J. De Zhu, “Correlation between methylation profile of promoter cpg islands of seven metastasis-associated genes and their expression states in six cell lines of liver origin,” Ai Zheng, vol. 23, no. 9, pp. 985–991, 2004. View at Google Scholar · View at Scopus
  32. S. Bhalerao and P. Kadam, “Sample size calculation,” International Journal of Ayurveda Research, vol. 1, no. 1, pp. 55–57, 2010. View at Publisher · View at Google Scholar
  33. E. Heitzer, P. Ulz, and J. B. Geigl, “Circulating tumor DNA as a liquid biopsy for cancer,” Clinical Chemistry, vol. 61, no. 1, pp. 112–123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Roth, K. Pantel, V. Müller et al., “Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression,” BMC Cancer, vol. 11, no. 1, article 4, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Sai, D. Ichikawa, H. Tomita et al., “Quantification of plasma cell-free DNA in patients with gastric cancer,” Anticancer Research, vol. 27, no. 4, pp. 2747–2751, 2007. View at Google Scholar · View at Scopus
  36. T.-L. Wu, D. Zhang, J.-H. Chia, K.-C. Tsao, C.-F. Sun, and J. T. Wu, “Cell-free DNA: measurement in various carcinomas and establishment of normal reference range,” Clinica Chimica Acta, vol. 321, no. 1-2, pp. 77–87, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Bettegowda, M. Sausen, R. J. Leary et al., “Detection of circulating tumor DNA in early- and late-stage human malignancies,” Science Translational Medicine, vol. 6, no. 224, Article ID 224ra24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Feng, X. Ye, F. Fang, C. Pu, H. Huang, and G. Li, “Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma,” Disease Markers, vol. 34, no. 2, pp. 105–111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Kienel, D. Porres, A. Heidenreich, and D. Pfister, “cfDNA as a prognostic marker of response to taxane based chemotherapy in patients with prostate cancer,” The Journal of Urology, vol. 194, no. 4, pp. 966–971, 2015. View at Publisher · View at Google Scholar
  40. Z. Chen, A. Fadiel, F. Naftolin, K. D. Eichenbaum, and Y. Xia, “Circulation DNA: biological implications for cancer metastasis and immunology,” Medical Hypotheses, vol. 65, no. 5, pp. 956–961, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Jung, M. Fleischhacker, and A. Rabien, “Cell-free DNA in the blood as a solid tumor biomarker—a critical appraisal of the literature,” Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1611–1624, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. A. Kamat, F. Z. Bischoff, D. Dang et al., “Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma,” Cancer Biology and Therapy, vol. 5, no. 10, pp. 1369–1374, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Cheng, M. Omura-Minamisawa, Y. Kang, T. Hara, I. Koike, and T. Inoue, “Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy,” Cancer Science, vol. 100, no. 2, pp. 303–309, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. R. Thierry, F. Mouliere, C. Gongora et al., “Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts,” Nucleic Acids Research, vol. 38, no. 18, pp. 6159–6175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Mouliere, B. Robert, E. Peyrotte et al., “High fragmentation characterizes tumour-derived circulating DNA,” PLoS ONE, vol. 6, no. 9, Article ID e23418, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Pinzani, F. Salvianti, S. Zaccara et al., “Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations,” Clinica Chimica Acta, vol. 412, no. 23-24, pp. 2141–2145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Lu, J. Busch, M. Jung et al., “Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients,” Clinica Chimica Acta, vol. 452, pp. 109–119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Hauser, T. Zahalka, J. Ellinger et al., “Cell-free circulating DNA: diagnostic value in patients with renal cell cancer,” Anticancer Research, vol. 30, no. 7, pp. 2785–2789, 2010. View at Google Scholar · View at Scopus
  49. J. Wan, L. Zhu, Z. Jiang, and K. Cheng, “Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma,” Urologia Internationalis, vol. 91, no. 3, pp. 273–278, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Fleischhacker and B. Schmidt, “Circulating nucleic acids (CNAs) and cancer—a survey,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, vol. 1775, no. 1, pp. 181–232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. V. V. Levenson, “DNA methylation as a universal biomarker,” Expert Review of Molecular Diagnostics, vol. 10, no. 4, pp. 481–488, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. A. M. Dworkin, T. H.-M. Huang, and A. E. Toland, “Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment,” Seminars in Cancer Biology, vol. 19, no. 3, pp. 165–171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. M. O. Hoque, “DNA methylation changes in prostate cancer: current developments and future clinical implementation,” Expert Review of Molecular Diagnostics, vol. 9, no. 3, pp. 243–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Warton and G. Samimi, “Methylation of cell-free circulating DNA in the diagnosis of cancer,” Frontiers in Molecular Biosciences, vol. 2, article 13, 2015. View at Publisher · View at Google Scholar
  55. P. P. Anglim, T. A. Alonzo, and I. A. Laird-Offringa, “DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update,” Molecular Cancer, vol. 7, article 81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Delpu, P. Cordelier, W. C. Cho, and J. Torrisani, “DNA methylation and cancer diagnosis,” International Journal of Molecular Sciences, vol. 14, no. 7, pp. 15029–15058, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Charlton, R. D. Williams, M. Weeks et al., “Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood,” Genome Biology, vol. 15, no. 8, article 434, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. T. C. Brown, C. C. Juhlin, J. M. Healy, M. L. Prasad, R. Korah, and T. Carling, “Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis,” JAMA Surgery, vol. 149, no. 11, pp. 1146–1152, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. M. K. Joo, K. H. Kim, J.-J. Park et al., “CpG island promoter hypermethylation of Ras association domain family 1A gene contributes to gastric carcinogenesis,” Molecular Medicine Reports, vol. 11, no. 4, pp. 3039–3046, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. X.-M. Wu, Y. Chen, Y. Shao, X.-L. Zhou, and W.-R. Tang, “Association between cigarette smoking and RASSF1A gene promoter hypermethylation in lung cancer patients: a meta- analysis,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 19, pp. 8451–8454, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. H.-L. Wang, P. Liu, P.-Y. Zhou, and Y. Zhang, “Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies,” Annals of Human Genetics, vol. 78, no. 3, pp. 208–216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. J.-G. Si, Y.-Y. Su, Y.-H. Han, and R.-H. Chen, “Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis,” Genetic Testing and Molecular Biomarkers, vol. 18, no. 6, pp. 394–402, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Daniunaite, S. Jarmalaite, N. Kalinauskaite et al., “Prognostic value of RASSF1 promoter methylation in prostate cancer,” The Journal of Urology, vol. 192, no. 6, pp. 1849–1855, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Shi, Y. Li, X. Wang et al., “Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis,” PLoS ONE, vol. 8, no. 10, Article ID e76787, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Spugnardi, S. Tommasi, R. Dammann, G. P. Pfeifer, and D. S. B. Hoon, “Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma,” Cancer Research, vol. 63, no. 7, pp. 1639–1643, 2003. View at Google Scholar · View at Scopus
  66. J. Ellinger, D. Holl, P. Nuhn et al., “DNA hypermethylation in papillary renal cell carcinoma,” BJU International, vol. 107, no. 4, pp. 664–669, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. V. V. Gordiyuk, G. V. Gerashchenko, I. Y. Skrypkina et al., “Identification of chromosome 3 epigenetic and genetic abnormalities and gene expression changes in ovarian cancer,” Biopolymers and Cell, vol. 24, no. 4, pp. 323–332, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. G. V. Gerashchenko, V. V. Gordiyuk, I. Y. Skrypkina et al., “Screening of epigenetic and genetic disturbances of human chromosome 3 genes in colorectal cancer,” Ukrainskiĭ Biokhimicheskiĭ Zhurnal, vol. 81, no. 4, pp. 81–87, 2009. View at Google Scholar · View at Scopus
  69. M. Kim, J.-H. Kim, H.-R. Jang et al., “LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer,” Cancer Research, vol. 68, no. 17, pp. 7147–7155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. A. G. Kondratov, K. A. Nekrasov, L. V. Lototska et al., “Comparative analysis of epigenetic markers in plasma and tissue of patients with colorectal cancer,” Biopolymers and Cell, vol. 30, no. 2, pp. 129–134, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Demokan, A. Y. Chuang, K. M. Pattani, D. Sidransky, W. Koch, and J. A. Califano, “Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer,” Oncology Reports, vol. 31, no. 2, pp. 1014–1020, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Takada, X. Ye, and S. Simon, “The integrins,” Genome Biology, vol. 8, no. 5, article 215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Mambole, S. Bigot, D. Baruch, P. Lesavre, and L. Halbwachs-Mecarelli, “Human neutrophil integrin α9β1: up-regulation by cell activation and synergy with β2 integrins during adhesion to endothelium under flow,” Journal of Leukocyte Biology, vol. 88, no. 2, pp. 321–327, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. D. G. Stupack and D. A. Cheresh, “Integrins and angiogenesis,” Current Topics in Developmental Biology, vol. 64, pp. 207–238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Rathinam and S. K. Alahari, “Important role of integrins in the cancer biology,” Cancer and Metastasis Reviews, vol. 29, no. 1, pp. 223–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Ghosh, S. Ghosh, G. P. Maiti et al., “Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: clinical and prognostic significance,” Cancer Science, vol. 101, no. 6, pp. 1511–1520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Häkkinen, T. Kainulainen, T. Salo, R. Grenman, and H. Larjava, “Expression of integrin α9 subunit and tenascin in oral leukoplakia, lichen planus, and squamous cell carcinoma,” Oral Diseases, vol. 5, no. 3, pp. 210–217, 1999. View at Google Scholar · View at Scopus
  78. S. Roy, L. Bingle, J. F. Marshall et al., “The role of α9β1 integrin in modulating epithelial cell behaviour,” Journal of Oral Pathology and Medicine, vol. 40, no. 10, pp. 755–761, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. A. M. Høye, J. R. Couchman, U. M. Wewer, K. Fukami, and A. Yoneda, “The newcomer in the integrin family: integrin α9 in biology and cancer,” Advances in Biological Regulation, vol. 52, no. 2, pp. 326–339, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Mitra, D. M. Indra, N. Bhattacharya et al., “RBSP3 is frequently altered in premalignant cervical lesions: clinical and prognostic significance,” Genes Chromosomes and Cancer, vol. 49, no. 2, pp. 155–170, 2010. View at Publisher · View at Google Scholar · View at Scopus